At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 69 enrolled
Drug / intervention
Tofacitinib ointment 20mg/g +1 moredrug
Likely dose
Tofacitinib ointment 20mg/gfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a, Multi-site, Randomized, Double-blind, Vehicle-controlled, Parallel-group Study Of The Pilot Efficacy, Safety, Tolerability, And Pharmacokinetics Of 2% Tofacitinib Ointment In Subjects With Mild To Moderate Atopic Dermatitis
In Brief
A Phase 2 clinical trial evaluating Tofacitinib ointment 20mg/g and Placebo ointment (Vehicle) for Dermatitis, Atopic. Completed, enrolled 69 participants across 5 sites.
Detailed Summary
The study is being conducted to evaluate the efficacy, safety and tolerability of 2% tofacitinib ointment (20 mg/g) BID (twice daily) in subjects with mild to moderate atopic dermatitis compared to placebo (vehicle) BID for 4 weeks.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDermatitis, Atopic
CountriesCanada
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartDec 2013
First PostedDec 2013
Primary CompletionSep 2014
TodayJul 2026
First PostedDec 4, 2013
Enrollment StartDec 1, 2013
Primary CompletionSep 1, 2014
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 12.6 years ago
Interventions
Tofacitinib ointment 20mg/gdrug
Tofacitinib ointment 20mg/g twice daily (BID) for 4 weeks
Placebo ointment (Vehicle)drug
Placebo ointment (vehicle) twice daily (BID) for 4 weeks